All News
20 years real-world data on disease burden, patient experience & unmet needs in Refractory #RheumatoidArthritis
▶️Higher glucocorticoid & opioid use
▶️Greater comorbidity & symptom burden
▶️More rheumatology visits
#ACR23
👉🏽https://t.co/CAUorjQbvN
by @KristinWipfler @Dr_K et al https://t.co/vx1aOZizfE
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
The Rheum Where It Happened! https://t.co/3gL5RLSNms
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Abstr#0571 As there is a genetic predisposition to #SLE, can polygenic risk score distinguish SLE vs ANA+ with no disease? A study in European ancestry showed modest discrimination (AUC: 0.66). This showed other contributors are vital in SLE development @RheumNowNews https://t.co/qiFOlOxq5r
Md Yuzaiful Md Yusof ( View Tweet)
OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH
TheDaoIndex KDAO2011 ( View Tweet)
Stop by the @rheumnow booth next to the ACR hub in the exhibit hall… we have fun trying to keep you current! BTW, watch us on the daily recap at https://t.co/kG93OYaNIx https://t.co/wuPxhyljgP
TheDaoIndex KDAO2011 ( View Tweet)
Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients
➡️May aid in monitoring joint damage
#ACR23
👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
ABS0433:
⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective
➡️Retrospect, obs using Medicare data
➡️At least 66 yo old w/ new dx of late-onset RA (LORA)
🚩If no contraindications, start DMARDs early in LORA!
#ACR23 @RheumNow https://t.co/ChalcgtS2O
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great work @sharoncowley01 https://t.co/llUF6REOFR https://t.co/Ej8fQlTNH0
Barry O'Shea ( View Tweet)
Great talk by @DrPujaMehta1
📦 out of the box!
#ACR23 #ACRambassador
@ACRheum https://t.co/dmr0m6W2ZP
Nelly ZIADE 🍀 Nellziade ( View Tweet)
⭐️Real world data on use of #avacopan presented by @zach_wallace_md
#vasculitis
Important observations to inform the practice and management of #AAV https://t.co/gtZORcnt9t
KenWarringtonMD MdWarrington ( View Tweet)
@gurdeep_dulay I ask the same question always, why would you stop denosumab? Nothing comes close to fully ameliorating the negative consequences of doing so. Denosumab is for life, until we figure out how to safely get off it. Don't start it unless that is acceptable #ACR23
Richard Conway ( View Tweet)
Fantastic presentation by @sharoncowley01 🚀
~1/5 patients with PMR have US evidence of Vasculitis at time of diagnosis without clinical signs of GCA
⬆️role of US in these patients https://t.co/wSs3IB8SU7 https://t.co/mAhFDVJJ8T
Caoilfhionn Connolly ( View Tweet)
The places to look for #enthesitis in #PsA in foot/ankle
#ACR2023 https://t.co/KxD7i5l5gS
Dr Gurdeep S Dulay ( View Tweet)
Super interesting study re: impact of ORAL SURVEILLANCE on prescribing
Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD)
I know many have mixed feelings, but I believe in the risk & support this type of shift
@RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1
Mike Putman EBRheum ( View Tweet)
ABS0450
⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients
➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97)
➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi
#ACR23 @RheumNow https://t.co/yydS20hNzM
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
No more underpowered long-term safety studies
We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA
Minus that, I plan to go 100% TOFA when it becomes generic in 2026
@RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
Mike Putman EBRheum ( View Tweet)
AS pts on UPA for 52 wks who were active or healthy weight/underweight at BL generally experienced greater decreases from BL in ASDAS-CRP and BASDAI vs pts who were inactive or overweight/obese. #ACR23 Abs #0540 https://t.co/OfgbmYUoAu @rheumno https://t.co/liptgbK2hJ
Dr. Rachel Tate ( View Tweet)
#ACR23
#SGLT2 inhibitors assoc with
⬇️ urate
⬇️ flares if #gout
⬇️mortality
impact on #metabolicSyndrome ✅ https://t.co/ZIqDqirqar
Dr Gurdeep S Dulay ( View Tweet)
#ACR23
Scleroderma renal Crisis (SRC)
May precede skin involvement also.
RISK FACTORS
• Early diffuse skin disease
- 2-3 years from SSc onset, median 8 months
• Anti-RNA polymerase III (60%)
• Use of corticosteroids
- >15 mg/d or low doses for longer time https://t.co/RSIxEXLdX7
Aditya Burje AdityaBurje ( View Tweet)
#ACR23 Abstr#0785 So many debates re: HCQ dose 5mg/kg/d vs 6.5mg/kg/d - could blood monitoring help? A cohort study showed HCQ levels 750-1100 ng/mL was associated with reduced risk of #lupus activity by 76-90%. Need validation & assoc with retinal toxicity risk @RheumNowNews https://t.co/oRCHUG2dVA
Md Yuzaiful Md Yusof ( View Tweet)